Trials / Terminated
TerminatedNCT05619172
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of SOT101 in Combination With Cetuximab in Patients With RAS Wild-type Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- SOTIO Biotech AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nanrilkefusp alfa | Subcutaneous (SC) injection |
| DRUG | Cetuximab | Intravenous (IV) infusion via peripheral or central venous line |
Timeline
- Start date
- 2022-12-22
- Primary completion
- 2024-03-06
- Completion
- 2024-06-05
- First posted
- 2022-11-16
- Last updated
- 2025-07-24
- Results posted
- 2025-07-24
Locations
8 sites across 3 countries: Belgium, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05619172. Inclusion in this directory is not an endorsement.